Poor
Not Aligned
Patient Risk:
High
Summary
Most statements about tigecycline-induced liver enzyme elevations/liver injury risk stratification and liver-related monitoring/stop criteria are not supported by the limited label excerpts provided (which include boxed all-cause mortality, limitations of use for specific infections, dosing, contraindications, and select other precautions). Only the final statement about holding/stopping tigecycline in significant symptomatic liver injury is partially consistent with general clinical hold/stop logic but still unsupported by the provided label text.
Category Scores
Accurate Statements
If liver injury is significant or symptomatic, clinicians may stop tigecycline and switch to an alternative based on the infection and culture results.
Not explicitly supported by the provided excerpts; however, it does not directly contradict any supplied label text.
Unsupported Statements
Tigecycline can raise liver enzymes.
The provided label excerpts do not mention hepatotoxicity, elevated liver enzymes, or liver enzyme monitoring.
Tigecycline can, in some cases, cause liver injury.
No liver injury/hepatotoxicity content is present in the supplied label excerpts.
The risk of tigecycline-related liver effects is higher in people with impaired liver function.
No statements in the provided excerpts address liver impairment and increased liver effects.
The risk of tigecycline-related liver effects is higher in people with other serious baseline illness.
No label excerpt provided discusses baseline illness increasing liver effects.
The risk of tigecycline-related liver effects is higher in those receiving tigecycline treatment for longer durations.
No label excerpt provided links duration to liver effects.
The risk of tigecycline-related liver effects is higher in those with higher drug exposure.
No label excerpt provided links exposure levels to liver effects.
The risk of liver effects is higher in patients with pre-existing hepatic impairment.
No hepatic impairment/liver effects content is included in the provided excerpts.
Tigecycline exposure is greater when the liver is already not working normally in patients with pre-existing hepatic impairment.
No pharmacokinetic/exposure statements for hepatic impairment are included in the provided excerpts.
The vulnerability to drug-related liver injury is greater when the liver is already not working normally.
No liver vulnerability/interaction with hepatic impairment content is included in the provided excerpts.
Patients with severe underlying conditions (including critical illness and other organ dysfunction) have a higher observed risk of abnormal liver tests during tigecycline treatment.
The provided label excerpts discuss mortality imbalance in pneumonia; they do not mention liver tests.
The higher observed risk of abnormal liver tests during tigecycline treatment in severe underlying conditions is partly because patients are more prone to abnormalities from both illness and medications.
Not present in the provided label excerpts.
Higher tigecycline exposure tends to correlate with more frequent liver test abnormalities.
No label excerpt provided describes correlation between exposure and liver test abnormalities.
Risk of liver test abnormalities can increase with longer tigecycline treatment courses because enzyme elevations may develop or worsen after several days of therapy.
No label excerpt provided addresses liver test abnormality timing/duration.
Patients are monitored for rising aminotransferases (ALT/AST) and other evidence of liver dysfunction during tigecycline treatment.
No liver monitoring (ALT/AST) guidance is included in the provided excerpts.
Worsening liver test results together with jaundice is used as a warning sign in deciding whether to hold or stop tigecycline.
No jaundice/liver test warning/hold/stop criteria are included in the provided excerpts.
Worsening liver test results together with dark urine is used as a warning sign in deciding whether to hold or stop tigecycline.
No dark urine/liver test warning/hold/stop criteria are included in the provided excerpts.
Worsening liver test results together with right upper abdominal pain is used as a warning sign in deciding whether to hold or stop tigecycline.
No right upper abdominal pain/liver test warning/hold/stop criteria are included in the provided excerpts.
Worsening liver test results together with unexplained fatigue is used as a warning sign in deciding whether to hold or stop tigecycline.
No unexplained fatigue/liver test warning/hold/stop criteria are included in the provided excerpts.
Clinicians evaluate for other contributors to liver injury in patients with liver enzyme elevations during tigecycline treatment, including viral hepatitis, biliary obstruction, alcohol use, other hepatotoxic drugs, and progression of underlying illness.
No label excerpt provided discusses differential evaluation of liver injury.
Contradictions
Important Omissions
All-cause mortality boxed warning risk framing (0.6% adjusted risk difference) and reserve-for-alternative-suitable-use statement.
Importance:
Moderate
Limitations of use: not indicated for hospital-acquired or ventilator-associated pneumonia; greater mortality and decreased efficacy in that setting.
Importance:
Moderate
Contraindication for known hypersensitivity to tigecycline or excipients.
Importance:
Moderate
Dosing regimen (initial 100 mg then 50 mg every 12 hours) and infusion duration (30 to 60 minutes every 12 hours).
Importance:
Moderate
Monitoring guidance present in provided excerpts (e.g., baseline fibrinogen/blood coagulation parameters and regular monitoring).
Importance:
Low
Safety Assessment
Potential Patient Risk:
High
The response contains many liver-related adverse event and monitoring/stop criteria claims that are not supported by the provided label excerpts. Overstating unlabelled hepatotoxicity risk and decision criteria may misdirect monitoring/clinical attention away from label-supported boxed warning and other provided safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of liver-enzymes/liver-injury/monitoring and hold-stop warning criteria are unsupported by the supplied TYGACIL label excerpts.
Suggested Improvement
Restrict safety statements to those explicitly present in the provided label text (boxed all-cause mortality and reserve-use language; mortality imbalance in HAP/VAP; contraindications; dosing; pediatric avoidance; and the provided monitoring of blood coagulation parameters). Remove or clearly qualify liver-specific claims unless the corresponding label sections are provided.